Evidence map›Paper›PMID 39660731›Full record

ArticleThe Journal of pathology2025

Stress testing deep learning models for prostate cancer detection on biopsies and surgical specimens.

Brennan T Flannery, Howard M Sandler, Priti Lal, Michael D Feldman, Juan C Santa-Rosario, Tilak Pathak, Tuomas Mirtti, Xavier Farre, Rohann Correa, Susan Chafe and 9 more

Abstract read
In one paragraph

Article in The Journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Brennan T FlanneryCase Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-0074-1779
Howard M SandlerCedars-Sinai Medical Center, Los Angeles, CA, USA.
Priti LalUniversity of Pennsylvania, Philadelphia, PA, USA.
Michael D FeldmanIndiana University, Indianapolis, IN, USA.
Juan C Santa-RosarioCorePlus, Carolina, Puerto Rico.
Tilak PathakEmory Winship Cancer Institute, Atlanta, GA, USA.
Tuomas MirttiEmory Winship Cancer Institute, Atlanta, GA, USA.
Xavier FarrePublic Health Agency of Catalonia, Catalonia, Spain.
Rohann CorreaLondon Health Science Centre, London, ON, Canada.
Susan ChafeCross Cancer Institute, Edmonton, AB, Canada.
Amit ShahWellSpan Health, York, PA, USA.
Jason A EfstathiouMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Karen HoffmanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark A HallmanFox Chase Cancer Center, Philadelphia, PA, USA.
Michael StrazaMedical College of Wisconsin, Milwaukee, WI, USA.
Richard JordanNRG Oncology Biospecimen Bank, San Francisco, CA, USA.
Stephanie L PughNRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
Felix FengUniversity of California San Francisco, San Francisco, CA, USA.
Anant MadabhushiEmory Winship Cancer Institute, Atlanta, GA, USA.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Elaina Harper · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
Prognostic and Predictive Digital Tissue Image Assay for Prostate CancerR01CA268287 · NCI · EMORY UNIVERSITY · PI GUPTA, SHILPA, LAL, PRITI · 2022 to 2025
$3.0M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Novel Radiomics for Predicting Response to Immunotherapy for Lung CancerR01CA257612 · NCI · EMORY UNIVERSITY · PI Anant Madabhushi, Vamsidhar Velcheti · 2021 to 2026
$2.7M
BLRD VA I01 BX004121Kidney Precision Medicine ProjectLung Cancer Research Program W81XWH-18-1-0440Lung Cancer Research Program W81XWH-20-1-0595National Heart, Lung and Blood Institute 1R01HL15127701A1National Heart, Lung and Blood Institute R01HL15807101A1NCI NIH HHS 1U01CA239055-01NCI NIH HHS 1U01CA248226-01NCI NIH HHS 1U54CA254566-01NCI NIH HHS R01 CA202752NCI NIH HHS R01CA202752-01A1NCI NIH HHS R01 CA208236NCI NIH HHS R01CA208236-01A1NCI NIH HHS R01 CA216579NCI NIH HHS R01CA216579-01A1NCI NIH HHS R01 CA220581NCI NIH HHS R01CA220581-01A1NCI NIH HHS R01 CA249992NCI NIH HHS R01CA249992-01A1NCI NIH HHS R01 CA257612NCI NIH HHS R01CA257612-01A1NCI NIH HHS R01CA26820701A1NCI NIH HHS R01 CA268287NCI NIH HHS R01CA268287A1NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U01 CA269181NCI NIH HHS U01CA269181NCI NIH HHS U10 CA180822NCI NIH HHS U10CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U10CA180868NCI NIH HHS U24 CA196067NCI NIH HHS U24CA196067NCI NIH HHS U54 CA254566NCI NIH HHS UG1 CA189867NCI NIH HHS UG1CA189867NIBIB NIH HHS 1R43EB028736-01NIBIB NIH HHS R43 EB028736Peer Reviewed Cancer Research Program W81XWH-18-1-0404Peer Reviewed Cancer Research Program W81XWH-21-1-0160Peer Reviewed Cancer Research Program W81XWH-21-1-0345Prostate Cancer Research Program W81XWH-20-1-0851The DoD Breast Cancer Research Program Breakthrough Level 1 Award W81XWH-19-1-0668United States Department of Veterans Affairs Biomedical Laboratory Research and Development ServiceVA Merit Review Award IBX004121A
6 · The paper itself

Abstract

The presence, location, and extent of prostate cancer is assessed by pathologists using H&E-stained tissue slides. Machine learning approaches can accomplish these tasks for both biopsies and radical prostatectomies. Deep learning approaches using convolutional neural networks (CNNs) have been shown to identify cancer in pathologic slides, some securing regulatory approval for clinical use. However, differences in sample processing can subtly alter the morphology between sample types, making it unclear whether deep learning algorithms will consistently work on both types of slide images. Our goal was to investigate whether morphological differences between sample types affected the performance of biopsy-trained cancer detection CNN models when applied to radical prostatectomies and vice versa using multiple cohorts (N = 1,000). Radical prostatectomies (N = 100) and biopsies (N = 50) were acquired from The University of Pennsylvania to train (80%) and validate (20%) a DenseNet CNN for biopsies (M

Indexed as

Deep LearningProstatectomyProstatic NeoplasmsBiopsyHumansMaleNeural Networks, Computerbiopsyconvolutional neural networksdeep learninggeneralizabilityinterpretabilitymachine learningmorphologyprostate cancerradical prostatectomy

Identifiers

PMID39660731
PMCPMC11717490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.